Eli Lilly and Roche ask CMS not to be lumped in with Aduhelm’s restrictive judgment
With CMS closing its public comment period for its draft decision to limit coverage of Biogen’s Aduhelm last week, two Big …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
